ArticleMemorias do Instituto Oswaldo Cruz2026
Paroxetine activity against Trypanosoma cruzi: in vitro and in vivo studies.
Article in Memorias do Instituto Oswaldo Cruz, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChagas disease (CD) lacks effective therapy. However, the long time and high financial investments for the development of new drugs are limiting obstacles. The repositioning of drugs is an interesting approach for novel antiparasitic medicines. Previous results suggest that paroxetine (PXT) may represent a promising anti-Trypanosoma cruzi agent.
objectivesOur aim was to evaluate the activity and cellular targets of PXT on T. cruzi infection in vitro and in vivo.
methodsPXT and benznidazole (BZ) were assayed against intracellular and bloodstream forms for different periods of incubation by colorimetric and light microscopy analysis. Bloodstream forms were exposed to PXT and observed by transmission electron microscopy. PXT alone and in combination with BZ was evaluated as an acute mouse model of T. cruzi infection.
findingsPXT is active (EC50 = 2.18 μM) against amastigotes of T. cruzi (Tulahuen-β gal strain), resulting in > 99% suppression of parasitism after 168 h of drug exposure. Upon bloodstream forms (Y strain), PXT was effective, displaying EC50 values of 8.90 and 4.27 μM after 2 and 24 h of incubation, respectively, revealing a rapid trypanocidal activity. PXT triggered ultrastructural alterations on trypomastigotes, including cytoplasmic disorganization, numerous contractile vacuoles besides damage on the mitochondria and paraflagellar stem. The proof of concept using a mouse model of acute T. cruzi infection demonstrates that although the parasitaemia was suppressed, PXT was unable to protect against mortality. MAIN
conclusionsOur findings demonstrate the activity of PXT against T. cruzi and reinforces the relevance of drug repositioning for CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.